Amgen are establishing a major new biologics manufacturing hub in North Carolina

Amgen is investing over $1.5 billion in its Holly Springs site — establishing a major new biologics manufacturing hub as part of its global network. The site is being developed as a multi-product drug substance facility, designed to support both stainless steel and single-use manufacturing — enabling flexibility across a growing pipeline of therapies, but facilities like this are not just large — they are highly dynamic.

🔷 Multiple production technologies operating in parallel
🔷 Flexible manufacturing setups supporting different products
🔷 Rapid scale-up of new processes and pipelines
🔷 Increasing coordination between production, engineering, and quality

This introduces a different type of complexity. Not just scale — but variability.
‍
🔷 Where is equipment located between runs?
🔷 How are systems configured today vs yesterday?
🔷 What changes between batches or products?
🔷 What is impacted when something is adjusted?
‍
In flexible, multi-product environments — operations are constantly changing, and maintaining clarity across that change is critical.Because the challenge isn’t just building capacity — it’s operating it with control.

At PlantQuest, we’re proud to spotlight initiatives that drive global pharmaceutical innovation. We look forward to continuing to support forward-thinking organisations as they set new benchmarks.